BioSante Pharmaceuticals, Inc. (BPAX)

[PETERDENIEL2003]

Biosante Pharmaceuticals Price / Book Value: 1.833

BPAX Price / Book Value Range, Past 5 Years
Minimum 1.833 Mar 14 2012
Maximum 22.32 Jun 2011
Average 6.406

http://ycharts.com/companies/BPAX/price_to_book_value#series=type:company,id:BPAX,calc:price_to_book_value,,id:BPAX,type:company,calc:price_to_book_value&zoom=5&startDate=&endDate=&format=real&recessions=false

AT PRESENT $57million in cash is the Key,

-TEVA has royalty payment against Bio T GEL is $5 MILLION /Annual + OTHER milestone payment of commercializing product in Market..


-BPAX has option to collect Elestrin Gel payment of $144 million, Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Jazz Pharmaceuticals, BioSante´s licensee.

- Aduro BioTech will pay for GVAX trials Phase II cancer clinical trials, most of which are being conducted in cooperation with The Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, and are sponsored or funded by others at no cost to BioSante

- BioSante also has a licensing agreement with Pantarhei Bioscience B.V. for the development of its patented Pill-Plus™ oral contraceptive. Pantarhei is engaged in several Phase II clinical studies with this product from which BioSante hopes to share additional clinical data later this year.

Read more here: http://www.sunherald.com/2012/03/13/3815...